+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06340516

Blood Test Monitoring of Heart Function During HER2-Targeted Treatment in HER2-Positive Breast Cancer Patients

Led by Vastra Gotaland Region · Updated on 2024-04-01

700

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating trastuzumab-induced cardiotoxicity TIC in patients with HER2-positive breast cancer who are receiving trastuzumab treatment before and after breast cancer surgery. The study aims to assess how well blood levels of NT-proBNP can detect TIC compared to the current standard heart function tests, echocardiography ECHO and Multigated Acquisition Scan MUGA. This national multicenter phase II trial focuses on patients planned for neoadjuvant or adjuvant treatment with HER2-blocking agents, following national guidelines for chemotherapy and antibody therapies. Participants will have baseline heart function tests ECHOMUGA and NT-proBNP blood tests before starting trastuzumab treatment. NT-proBNP levels will then be measured again at 6 months and 12 months during treatment. If NT-proBNP levels rise at these times, patients will be referred for additional ECHOMUGA scans. This approach is being studied as a possible replacement for routine ECHOMUGA scans to reduce the need for more labor-intensive procedures. During the trial, participants will undergo heart function monitoring through blood tests and imaging scans at specified intervals. Researchers will measure the sensitivity and specificity of NT-proBNP in detecting cardiac dysfunction caused by trastuzumab from the start of treatment up to 24 months later. The study also tracks the prevalence of cardiotoxicity and changes in NT-proBNP related to anthracycline chemotherapy. Participants will be monitored closely with tests and follow-up visits to evaluate heart health and treatment effects over time.

CONDITIONS

Brief Title

NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity

Research Team

D

Daniel Giglio, Assoc Prof

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here